Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Total Current Liabilities (2024 - 2025)

Humacyte has reported Total Current Liabilities over the past 2 years, most recently at $18.4 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $18.4 million for Q4 2025, down 7.93% from a year ago — trailing twelve months through Dec 2025 was $18.4 million (down 7.93% YoY), and the annual figure for FY2025 was $18.4 million, down 7.93%.
  • Total Current Liabilities for Q4 2025 was $18.4 million at Humacyte, down from $25.6 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for HUMA hit a ceiling of $25.6 million in Q3 2025 and a floor of $14.1 million in Q1 2024.